Sanofi Awaiting Key Meeting With FDA To Recommence Cialis Switch

Sanofi is waiting to hear from FDA whether it has done enough to recommence its Cialis actual-use trial, which has been on hold for almost two years. The France-based firm gave an update on the Cialis switch program as it reported higher Consumer Healthcare sales in Q4.

• Source: Shutterstock

Sanofi Consumer Healthcare expects to find out before the end of the quarter whether its program to switch erectile dysfunction drug Cialis in the US can get back underway after a long delay.

Since the US Food and Drug Administration paused Sanofi’s application back in May 2022, the company has been working on...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health